When Is Prenatal Genetic Screening Usually Offered?

When Screening Enters Prenatal Care

Prenatal genetic screening may be offered as part of pregnancy care, but deciding whether to have it is a personal choice. These tests estimate the chance of certain conditions; they do not confirm a diagnosis. The American College of Obstetricians and Gynecologists’ guidance on prenatal screening explains how screening differs from diagnostic testing.

The timing of a test depends on what it measures and the needs of the individual pregnancy. Some options are available early, while others are performed later, so it helps to discuss timing during prenatal visits. Raveco Medical personalizes obstetric and gynecologic care to each patient, creating space to ask questions and consider which options fit.

This guide outlines common testing windows, what screening may tell families, and what follow-up could involve. A prenatal care provider can explain the possible benefits and limits of each test, interpret results, and help weigh next steps. Patients may also choose to decline screening or diagnostic testing.

Start With Your First Prenatal Visit

Schedule a prenatal visit as soon as you know you’re pregnant. Many people have their first appointment during the first trimester, though the best timing can vary with personal health and circumstances. For more on preparing and what to expect, see this guide to your first prenatal visit.

The visit often starts with a review of your medical, family, and pregnancy history, including current medications and any previous pregnancies. Your care team may check your health, estimate your due date, and recommend or perform tests such as blood work. They can also discuss nutrition, prenatal vitamins, and questions or support needs you want addressed.

Prenatal care is tailored to each person. At a first visit with Raveco Medical, a women-led obstetrics and gynecology practice in Queens, you can raise questions about genetic screening options and when they may be offered. Ask what happens next, and contact your provider promptly if you have an urgent concern.

Routine Tests Across Pregnancy

Routine prenatal tests help your care team check your health and identify issues that may need follow-up. At an early visit, often in the first trimester, blood work commonly checks blood type and Rh status, complete blood count, immunity to rubella and sometimes varicella, and infections such as HIV, hepatitis B and C, and syphilis. Urine testing or a urine culture may also be offered. Your clinician will recommend tests based on your health history and the care you need. For a broader overview of routine tests during prenatal visits, see our related guide.

These tests are distinct from genetic screening, which estimates the chance of certain conditions and is optional. Some genetic screening, including cell-free DNA testing, may be available from about 10 weeks, while other options have different timing. Your clinician can explain what each test can and cannot show, as described in ACOG’s prenatal screening guidance.

Later in pregnancy, maternal serum alpha-fetoprotein (AFP) screening may be offered between 15 and 22 weeks, followed by an anatomy ultrasound, typically at 18 to 22 weeks. Gestational diabetes screening is usually offered at 24 to 28 weeks. Repeat blood counts and an antibody screen for Rh-negative patients may also be appropriate around this stage. Group B strep screening is generally done with a vaginal and rectal swab at 36 to 37 weeks. Ask your clinician which tests apply to you and when to schedule them.

Screening Estimates Risk, Diagnosis Confirms

Prenatal screening and diagnostic testing answer different questions. Screening estimates the chance of selected genetic or chromosomal conditions, while diagnostic testing can provide a more definitive answer about the conditions it examines. The American College of Obstetricians and Gynecologists’ guidance on prenatal screening explains that a higher-risk screening result does not confirm a condition.

Screening methods vary. Blood tests assess substances in the pregnant person’s blood, while cell-free DNA screening looks at placental DNA fragments circulating in the blood. Some screening uses ultrasound measurements or checks fetal anatomy. An ultrasound can identify certain features, but it is not automatically a diagnostic genetic test.

Diagnostic testing may be discussed when screening suggests increased risk or when personal circumstances raise concern. Chorionic villus sampling (CVS) takes a small sample of placental cells; amniocentesis collects a sample of amniotic fluid. Both are invasive procedures and can carry risks, including bleeding, infection and miscarriage. Your clinician can explain what each test can and cannot show.

Screening results can be false-positive or false-negative, so a positive result is not a diagnosis and a negative result cannot rule out every condition. A provider or genetic counselor can review the result, explain possible limitations and discuss whether diagnostic follow-up makes sense. The choice to have screening or diagnostic testing is personal, and a conversation with your pregnancy-care team can help clarify benefits, risks and next steps.

Raveco Medical provides personalized obstetrics and gynecology care in Queens, where patients can discuss testing questions with their care team.

The Main Screening Windows

Prenatal test timing depends on what a test looks for and what information you want. Your care team can review the options with you; ACOG’s prenatal testing guidance also notes that screening choices are offered at different points in pregnancy.

Carrier screening, which checks whether a parent carries certain inherited gene changes, can be done before or during pregnancy. Cell-free DNA screening, also called noninvasive prenatal testing (NIPT), is available starting at 10 weeks. First-trimester screening may combine a blood test with a nuchal translucency ultrasound, usually performed between 11 and 14 weeks. The Cleveland Clinic’s timing overview describes these options and their purposes.

Serum screening is not performed before 11 weeks. Later in pregnancy, quad screening and alpha-fetoprotein (AFP) screening are generally offered between 15 and 22 weeks. These blood tests assess risk for selected conditions; they do not confirm a diagnosis.

The anatomy ultrasound is a separate assessment, not a genetic screening blood test. Usually performed around 18 to 20 weeks according to Cleveland Clinic, or between 18 and 22 weeks in ACOG’s guidance, it examines fetal structures such as the heart, brain, spine and limbs.

Diagnostic procedures have their own windows: chorionic villus sampling (CVS) is generally performed around 11 to 13 weeks, while amniocentesis is usually performed between 16 and 20 weeks. The right timing and available options can vary with the test and individual circumstances. At Raveco Medical, prenatal care is part of personalized obstetrics and gynecology services in Queens, where patients can discuss timing and next steps with their care team.

NIPT Timing and Its Limits

Non-invasive prenatal testing (NIPT), also called cell-free DNA screening, can generally be done starting at 10 weeks of pregnancy, according to ACOG and the Cleveland Clinic. If you are 9 weeks pregnant, it may be too early under these recommendations. Ask your prenatal care provider when testing is appropriate for you.

At 14 weeks, it is generally not too late to discuss NIPT. Availability and timing can depend on your care and the options offered, so confirm with your provider. At Raveco Medical, prenatal care is part of comprehensive obstetrics and gynecology services, with care tailored to individual needs.

The blood test analyzes small fragments of placental DNA circulating in the pregnant person's blood and estimates the chance of certain chromosome conditions. It is a screening test, not a diagnosis. A higher-risk result does not confirm that a condition is present.

If a result is positive or unclear, your provider may discuss genetic counseling and offer diagnostic testing, such as chorionic villus sampling or amniocentesis, for more definitive information. You can also ask about other screening options, their timing and limitations, and what follow-up could involve. Testing is optional, and the choice is yours.

Conditions Screening May Assess

Prenatal genetic screening can estimate the chance of certain chromosome conditions. Common targets include Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13), though the conditions included depend on the test selected. ACOG’s guidance on prenatal screening explains that screening results estimate risk rather than confirm a condition.

Some cell-free DNA tests also screen for differences in the number of sex chromosomes, such as Turner syndrome, Klinefelter syndrome, Triple X syndrome, or XYY syndrome. Screening panels do not cover every genetic condition or birth difference, so ask your pregnancy care clinician what a particular test assesses and what it does not.

Carrier screening is different from screening the fetus. It checks whether a parent carries gene changes associated with inherited conditions, including cystic fibrosis, spinal muscular atrophy, and certain hemoglobin disorders. If a person is found to be a carrier, the clinician may discuss testing the other parent and what the results could mean.

A higher-risk screening result is not a diagnosis. A clinician can explain the result and discuss whether diagnostic testing, such as chorionic villus sampling (CVS) or amniocentesis, is appropriate. At Raveco Medical, prenatal care is part of personalized obstetrics and gynecology services, where test choices and follow-up can be discussed in the context of an individual pregnancy.

Sex Prediction Is Not Diagnostic

Cell-free DNA screening may offer an early estimate of fetal sex by analyzing placental DNA fragments in the pregnant person’s blood, including whether Y-chromosome DNA is detected. NIPT can predict fetal sex with about 98 to 99% accuracy when performed at or after 10 weeks, but accuracy varies by test and individual circumstances. ACOG explains that cell-free DNA screening can provide information about fetal sex, while emphasizing that screening results are not a diagnosis.

A result is not certain. Testing too early or having a low fetal fraction, meaning too little placental DNA in the blood sample, may affect the result. Twins, a vanished twin, and rare biological factors can also complicate interpretation.

At Raveco Medical, prenatal care is part of personalized obstetrics and gynecology services in Queens, where patients can discuss screening questions with their pregnancy-care provider. Ask how your individual result should be interpreted and whether follow-up is appropriate. For more on the limits of this result, see how cell-free DNA testing relates to fetal sex.

Age Is One Part of the Picture

Age can affect the chance of some chromosome conditions, including trisomy 21, but it does not determine which prenatal tests you should have. Screening and diagnostic testing should be offered to all pregnant patients, whatever their age, and testing remains a personal choice.

Being 35 or older does not automatically mean you need a different test or a diagnostic procedure. Screening estimates the chance of a condition, while diagnostic tests such as chorionic villus sampling (CVS) or amniocentesis can provide a more definite answer and have different benefits and risks. ACOG’s guidance on prenatal screening explains that results indicate risk, not certainty.

The choice may depend on your health and family history, the circumstances of your pregnancy, your preferences, and how much information you want. At Raveco Medical, prenatal care is part of personalized obstetrics and gynecology services, where testing options can be discussed in the context of your individual care.

Ask your obstetric provider or a genetic counselor what each test can and cannot tell you, what follow-up might involve, and how results could affect your care. You can make the decision that best fits your needs, including choosing not to test.

Carrier Screening Before Pregnancy

Carrier screening checks whether a person carries gene changes linked to inherited conditions. It can be done before pregnancy or during pregnancy, but testing before conception or early in pregnancy may leave more time to consider results, test a partner, and discuss possible next steps. Ask your clinician about planning carrier screening before pregnancy.

If both partners carry a change in the same recessive-condition gene, each pregnancy has a one-in-four chance of being affected, according to a review of prenatal genetic screening guidance. Screening may focus on a family history or use a broader panel. A negative result lowers the chance of carrying the tested conditions, but cannot rule it out completely.

Testing is optional. An obstetrician-gynecologist or genetic counselor can explain available tests, help interpret results, and discuss whether partner testing or other follow-up makes sense. Raveco Medical provides personalized obstetrics and gynecology care in Queens, where patients can raise questions about family history and pregnancy planning with their care team.

Check Coverage Before Testing

Insurance may cover NIPT and other prenatal genetic tests, but coverage depends on your plan, the specific test and your clinical circumstances. Even when a test is covered, you may still owe part of the cost.

Before scheduling, ask your insurer whether the test requires prior authorization and whether your deductible, copay or coinsurance applies. Request a written estimate from the laboratory, too, since your final cost may depend on how the claim is processed.

If the estimate is difficult to manage, ask the laboratory about a self-pay rate or financial assistance. For more information on what coverage may and may not include, ask your insurer and laboratory.

Your prenatal care provider can explain which tests may fit your care and why, while your insurer and laboratory can confirm payment details. At Raveco, prenatal care is personalized, so you can discuss testing options with your care team and then verify expected costs directly before deciding.

Make the Timing Work for You

Screening options become available at different stages of pregnancy, and the right schedule depends on the test and your circumstances. Testing is optional, so you can discuss choices with your care team without feeling that you must accept every test offered. ACOG’s guidance on prenatal screening explains that screening estimates risk, while diagnostic testing can provide a more definitive answer.

At a prenatal visit, ask which tests are available now and what each can and cannot show. You can also ask what follow-up might involve if a result indicates increased risk, including whether diagnostic testing or genetic counseling could be considered.

Consider how information might affect your prenatal care or help you prepare for a baby’s needs. The care team at Raveco Medical can discuss your pregnancy care and testing questions in the context of your individual circumstances, so you can make an informed choice that feels right for you.